Plus   Neg

K+S Q2 EBITDA Declines - Quick Facts

K+S (SDFG) reported second quarter EBITDA of 88 million euros compared to 130 million euros, previous year. Revenues declined to 840 million euros from 878 million euros.

For 2020 as a whole, K+S continues to expect EBITDA before one-off restructuring expenses of about 520 million euros. After taking into account these one-off expenses, the company projects EBITDA of about 480 million euros.

"The process to fully divest the Americas operating unit is progressing well, despite the ongoing corona pandemic. I am very confident that we will reach an agreement on the sale before the end of the year," said Burkhard Lohr, Chairman of the Board of Executive Directors of K+S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT